MNG361
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.397
- NOTCH_SIGNALING+0.356
- TGF_BETA_SIGNALING+0.348
- MYC_TARGETS_V1+0.285
- DNA_REPAIR+0.278
- UV_RESPONSE_DN+0.274
- PI3K_AKT_MTOR_SIGNALING+0.267
- PROTEIN_SECRETION+0.247
- MYC_TARGETS_V2+0.245
- MITOTIC_SPINDLE+0.241
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.412
- ANGIOGENESIS-0.384
- PANCREAS_BETA_CELLS-0.367
- HYPOXIA-0.310
- CHOLESTEROL_HOMEOSTASIS-0.306
- KRAS_SIGNALING_DN-0.271
- COAGULATION-0.266
- ESTROGEN_RESPONSE_LATE-0.251
- XENOBIOTIC_METABOLISM-0.240
- ESTROGEN_RESPONSE_EARLY-0.201
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG812 | — | — | 0.815 |
| 2 | MNG714 | — | — | 0.812 |
| 3 | MNG196 | — | — | 0.804 |
| 4 | SRR934853 | — | — | 0.797 |
| 5 | 4A2E75AE-A92F-4497-9253-64AC42CFA745 | — | — | 0.786 |
| 6 | SJEPD031236_D1.RNA-Seq | EPN | Supratentorial EPN | 0.784 |
| 7 | SRR934847 | — | — | 0.781 |
| 8 | 961CEC20-67F2-4615-8725-F35C12F0BC9B | — | — | 0.775 |
| 9 | 848C73F3-ABD7-47FD-BF70-FF29FBDF6F61 | — | — | 0.768 |
| 10 | SRR934880 | — | — | 0.765 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.397 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.356 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.348 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.285 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.278 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.274 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.267 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.247 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.245 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.241 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.227 | Inavolisib | — uncovered |
| PEROXISOME | 0.157 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.126 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.115 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.101 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.083 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.070 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.065 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.059 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.007 | Temsirolimus | — uncovered |